Back to search

Aristotle University Of Thessaloniki (AUTH)

Υιοθετούμενη ανοσοθεραπεία με αντιγονο-ειδικά Τ-λεμφοκύτταρα έναντι παθογόνων και καρκίνου

Abstract

dc:description

Allogeneic hematopoietic cell transplantation (allo-HSCT), in which stem hematopoietic stem cells are derived from a healthy donor, is the only radical treatment to date for poor prognosis leukemia. Despite the significant scientific progress that has been made in the field and the better training of medical staff today compared to previous decades, serious transplant complications have not been fully addressed. Two of the most important complications are recurrence of the disease and viral infections. Donor lymphocyte infusions (DLIs) can cause haematological remission after relapse in transplant patients, even without prior chemotherapy. However, T cells’ alloreactivity against antigens other than leukemic clones is associated with an increased risk of developing graft-versus-host disease (GvHD). T-cell immunotherapy with chimeric antigen receptors (CAR-Ts) or genetically modified T-cell receptor (TCR) has opened new horizons for the treatment of malignancies. However, the lack of appropriate target antigens in malignant myeloid cells renders CAR-T treatment ineffective in patients with refractory acute myeloid leukemia, while the incorrect coupling of the artificial with the endogenous TCR and restrictive barriers of the HLA system significant barriers to the wider clinical application of TCR-Ts.On the other hand, viral infections are a major cause of transplant-related morbidity and mortality (17-20%), significantly increasing the financial cost. In cases of previous exposure of the donor to specific pathogens, DLIs contain pathogen-specific memory T cells, capable of treating the infection through the action of the graft against infections [Graft vs Infection (GvI)]. However, their wider application in the treatment of post-transplant viral infections is limited by the low frequency of anti-viral T cells and the high frequency of alloreactive T cells.Utilizing the cytotoxic activity of the cells of the immune system with the adopted transfer of anti-viral or anti-cancer T cells, can significantly help in the treatment of viral infections and recurrences of leukemia after allo-HSCT. The unique ability of Dendritic Cells (DCs) to induce the production of specific immune responses by naive T cells raises a research interest so that they can be used in cellular immunotherapy of infections in immunocompromised patients and of advanced stage malignancies. However, their low blood content and the complex / expensive methodology of their generation by blood monocytes, prevent their widespread clinical use. An alternative source of DCs generation are hematopoietic stem cells (CD34+ cells), however, access to CD34+ cell sources is limited and the number of DCs produced is rarely sufficient for clinical application. On the other hand, non-transplantable umbilical cord blood units (UCBU) could be an immediately available, source of CD34+ cells for DCs generation.Ιn the following dissertation we investigated the possibility of producing non-genetically modified, specific T cells against leukemia-related antigens, (leukemia-specific T cells - Leuk-STs) Leuk-STs specific for Wilms Tumor 1 antigens (WT1), Expressed Antigen in Melanoma (PRAME) and also, against leukemia-related antigens and viral antigens simultaneously (LEukemia-VIrus specific T cells - LEVIS) LEVIS specific for WT1, PRAME, TERT (Telomerase Reverse Transcriptase), Survivin and for cytomegalovirus (CMV), human adenovirus (HAdV), EpsteinBarr (EBV) and Polyoma Virus (BK) antigens from UCBUs deemed unsuitable for allogeneic hematopoietic cell transplantation. Taking advantage of the non-transplanted UCBUs and optimizing the culture conditions, we achieved the production of myeloid DCs from CD34+ cells in clinically translatable doses. The produced DCs were used as antigen-presenting cells to perform multiple stimulations of autologous, naive T cells to produce clinically translatable doses of polyclonal Leuk-STs and LEVIS. The specific T cells produced contained CD8+ and CD4+ T-cell subpopulations, expressed memory markers and maintained very low or barely detectable expression levels of PD-1, CTLA4, TIM3 and LAG3 throughout culture, suggesting that prolonged exposure to antigens did not adversely affect their phenotype and Th-1 function in vitro. Furthermore, they showed strong specificity against all targeted antigens (WT1, PRAME and WT1, PRAME, TERT, Survivin, CMV, AdV, EBV, BKV) and strong cytotoxic activity in vitro.Overall, we provide an example of a circular economy utilizing non-transplantable UCBUs and a platform for the future creation of Leuk-STs and / or LEVIS banks as readily available, off-the-shelf "third party" cellular products and a cost-effective treatment for many patients with opportunistic infections that do not respond to standard antiviral medication or with recurrent leukemias after hematopoietic cell transplantation.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koukoulias, Kyriakos
  • Κουκουλιάς, Κυριάκος

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52041

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koukoulias, Kyriakos; Κουκουλιάς, Κυριάκος. Υιοθετούμενη ανοσοθεραπεία με αντιγονο-ειδικά Τ-λεμφοκύτταρα έναντι παθογόνων και καρκίνου. Aristotle University Of Thessaloniki (AUTH), 2022. http://hdl.handle.net/10442/hedi/52041